FrancophonIA/ELRC3.0 huggingface dataset:
English: The company that markets Zoledronic Acid Accord will provide a card to inform patients receiving Zoledronic Acid Accord about the risk of osteonecrosis of the jaw and to instruct them to contact their doctor if they get symptoms.
Estonian: Turustaja varustab ravimit Zoledronic Acid Accord kasutavad patsiendid teabekaardiga, milles neid teavitatakse lõualuu osteonekroosi riskist ning soovitatakse neil sümptomite tekkimisel pöörduda arsti poole.
English: Therefore, the Agency's view was that, as for Zometa, the benefit outweighs the identified risk and it can be authorised for use in the EU.
Estonian: Seetõttu oli amet arvamusel, et nagu ka Zometa korral, ületab ravimi Zoledronic Acid Accord kasulikkus sellega kaasnevad riskid ja seda võib kasutada ELis.
English: Because Zoledronic Acid Accord is a generic medicine, its benefits and risks are taken as being the same as the reference medicines'.
Estonian: Et Zoledronic Acid Accord on geneeriline ravim, peetakse ravimi kasulikkust ja riske samadeks mis võrdlusravimitel.
English: As for every medicine, the company provided studies on the quality of Zoledronic Acid Accord.
Estonian: Nagu iga ravimi korral, esitas ettevõte ravimi Zoledronic Acid Accord kvaliteedi uuringud.
English: Zoledronic Acid Accord is a medicine used to prevent bone complications in adults with advanced cancer that is affecting the bone.
Estonian: Ravimit Zoledronic Acid Accord kasutatakse luutüsistuste ennetamiseks täiskasvanud patsientidel, kellel on kaugelearenenud vähk, mis kahjustab luukude.
English: Zoledronic Acid Accord can also be used to treat hypercalcaemia caused by tumours.
Estonian: Ravimit Zoledronic Acid Accord tohib kasutada ka kasvajast põhjustatud hüperkaltseemia raviks.
English: What is Zoledronic Acid Accord and what is it used for?
Estonian: Mis on Zoledronic Acid Accord ja milleks seda kasutatakse?
English: The medicine is given as an infusion (drip) into a vein.
Estonian: Ravimit manustatakse veeniinfusioonina.
English: By preventing the breakdown of bones, Zoledronic Acid Accord also helps to reduce the amount of calcium released into the blood.
Estonian: Luukoe lagunemist peatades aitab Zoledronic Acid Accord vähendada verre eralduva kaltsiumi kogust.
English: Zoledronic Acid Accord (zoledronic acid)
Estonian: Zoledronic Acid Accord (soledroonhape)
English: There was no need for ‘bioequivalence' studies to investigate whether Zoledronic Acid Accord is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood.
Estonian: Ravimi bioekvivalentsust, st kas Zoledronic Acid Accord imendub organismis samamoodi nagu võrdlusravim, et saavutada toimeaine sarnane sisaldus veres, ei olnud vaja uurida.
English: The reduction of bone loss helps to make bones less likely to break, which is useful in preventing fractures in cancer patients with bone metastases.
Estonian: muutes luud murdudele vastupidavamaks, mis aitab ennetada luumurdude teket luumetastaasidega vähipatsientidel.
English: An overview of Zoledronic Acid Accord and why it is authorised in the EU
Estonian: Ülevaade ravimist Zoledronic Acid Accord ja ELis müügiloa väljastamise põhjendus
English: Zoledronic Acid Accord contains the active substance zoledronic acid and is a ‘generic medicine'.
Estonian: Ravim Zoledronic Acid Accord sisaldab toimeainena soledroonhapet ja on geneeriline ravim.
English: When used to prevent bone complications, the infusion can be repeated every three to four weeks, and patients should also take supplements of calcium and vitamin D. A lower dose is recommended for patients with bone metastases (when cancer has spread to the bone) if they have mild to moderately reduced kidney function.
Estonian: Kui ravimit kasutatakse luutüsistuste ennetamiseks, tohib infusiooni korrata iga 3-4 nädala tagant ning patsiendid peavad lisaks võtma kaltsiumi ja D-vitamiini.
English: This is because Zoledronic Acid Accord is given by infusion into a vein, so the active substance is delivered straight into the bloodstream.
Estonian: Seda ei olnud vaja, sest ravimit Zoledronic Acid Accord manustatakse veeniinfusioonina, mille abil satub toimeaine otse vereringesse.
English: Other information about Zoledronic Acid Accord
Estonian: Muu teave ravimi Zoledronic Acid Accord kohta
English: The active substance in Zoledronic Acid Accord, zoledronic acid, is a bisphosphonate.
Estonian: Ravimi Zoledronic Acid Accord toimeaine soledroonhape on bisfosfonaat.
English: How is Zoledronic Acid Accord used?
Estonian: Kuidas ravimit Zoledronic Acid Accord kasutatakse?
English: How does Zoledronic Acid Accord work?
Estonian: Kuidas Zoledronic Acid Accord toimib?
English: How has Zoledronic Acid Accord been studied?
Estonian: Kuidas ravimit Zoledronic Acid Accord uuriti?
English: It is not recommended for patients with severely reduced kidney function.
Estonian: Ravimit Zoledronic Acid Accord ei soovitata patsientidele, kellel on raske neerupuudulikkus.
English: What are the benefits and risks of Zoledronic Acid Accord?
Estonian: Milles seisneb ravimi Zoledronic Acid Accord kasulikkus ja mis riskid ravimiga kaasnevad?
English: This will help protect against the disease.
Estonian: See aitab kaitsta haiguse eest.
English: Protection starts 21 days after vaccination and lasts for 112 days.
Estonian: Kaitse algab 21 päeva pärast vaktsineerimist ja kestab 112 päeva.
English: The full EPAR for Vepured can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Vepuredi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: What is Vepured and what is it used for?
Estonian: Mis on Vepured ja milleks seda kasutatakse?
English: The European Commission granted a marketing authorisation valid throughout the EU for Vepured on 17 August 2017.
Estonian: Euroopa Komisjon andis Vepuredi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 17/08/2017.
English: E. coli verotoxoid vaccine (inactivated recombinant)
Estonian: E. coli verotoksoid-vaktsiin (inaktiveeritud rekombinantne)
English: Why is Vepured approved?
Estonian: Miks Vepured heaks kiideti?
English: Vepured also reduced the weight loss of pigs in herds affected with the disease.
Estonian: Vepured vähendas ka põrsaste kaalulangust haigestunud karjades.
English: It results in damage to blood vessels, causing fluid build up in the tissues of the stomach and bowel and affecting the blood supply of the brain, and can lead to death within 24 to 48 hours.
Estonian: See kahjustab veresooni, mille tagajärjel tekib mao ja soole kudedes vedelikupeetus ja esineb aju verevarustushäireid, ning see võib põhjustada surma 24-48 tunni jooksul.
English: What are the risks associated with Vepured?
Estonian: Mis riskid Vepurediga kaasnevad?
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Vepured's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Veterinaarravimite komitee järeldas, et Vepuredi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Oedema disease is found worldwide and usually occurs in the first few weeks of life of the piglets.
Estonian: Tursetõbe esineb kogu maailmas, tavaliselt põrsaste esimestel elunädalatel.
English: The withdrawal period for meat from pigs treated with Vepured is ‘zero' days, which means there is no mandatory waiting time.
Estonian: Vepurediga ravitud sigade liha keeluaeg on 0 päeva, mis tähendab, et keeluaega ei ole.
English: It is not intended to provide practical advice on how to use Vepured.
Estonian: Hindamisaruandes ei anta Vepuredi kasutamise praktilisi nõuandeid.
English: The most common side effects with Vepured (which may affect more than 1 in 10 animals) are mild inflammation at the injection site that resolves within 3 days of vaccination without treatment, mild depression on the day of vaccination and an increase in body temperature of maximum 1.1 °C which returns to normal within 1 day.
Estonian: Vepuredi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 loomal 10st) on kerge põletik süstekohal, mis kaob ravita kolme päeva jooksul pärast vaktsineerimist, kerge depressioon vaktsineerimispäeval ja kehatemperatuuri tõus maksimaalselt 1,1 °C, mis normaliseerub ühe päevaga.
English: This is a summary of the European public assessment report (EPAR) for Vepured.
Estonian: See on vaktsiini Vepured Euroopa avaliku hindamisaruande kokkuvõte.
English: A field study involving 2- to 3-day-old piglets, 1,173 of which were vaccinated with Vepured and 1,048 piglets given a dummy injection, showed that Vepured prevented death of virtually all the piglets from oedema disease over a 115 day period and there was a significant reduction in signs of the disease which included difficulty breathing, oedema (fluid retention) and signs related to the nervous system.
Estonian: 2- kuni 3-päevaseid sigu hõlmanud väliuuringust, kus vaktsineeriti 1173 põrsast Vepurediga ja 1048 põrsale tehti näiva ravimi süst, ilmnes, et Vepured hoidis ära peaaegu kõigi põrsaste surma tursetõppe 115-päevasel perioodil ning oluliselt vähenes haigusnähtude (hingamisraskused, tursed (vedelikupeetus) ja närvisüsteemiga seotud nähud) esinemine.
English: Other information about Vepured:
Estonian: Muu teave Vepuredi kohta
English: Vepured contains verotoxin 2e that has been modified and inactivated so it can no longer cause disease.
Estonian: Vepured sisaldab verotoksiin 2e-d, mis on modifitseeritud ja inaktiveeritud, et see ei põhjustaks haigust.
English: For practical information about using Vepured, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Estonian: Kui loomaomanikud või -pidajad vajavad Vepuredi kasutamise praktilisi nõuandeid, peavad nad lugema pakendi infolehte või pöörduma oma veterinaararsti või apteekri poole.
English: Vepured is a vaccine containing modified, inactivated verotoxin 2e.
Estonian: Vepured on vaktsiin, mis sisaldab modifitseeritud inaktiveeritud verotoksiin 2e-d.
English: Vepured is a veterinary vaccine used to protect piglets against oedema disease (caused by verotoxin 2e produced by E. coli) and to reduce the loss of daily weight gain until slaughter.
Estonian: Vepured on veterinaarvaktsiin, mida kasutatakse põrsaste kaitsmiseks tursetõve eest (mida põhjustab E. coli toodetav verotoksiin 2e) ja päevase kaaluiibe languse vähendamiseks tapmiseelsel perioodil.
English: When Vepured is given to pigs, the animal's immune system recognises the toxin contained in the vaccine as ‘foreign' and makes antibodies against it.
Estonian: Kui sigadele manustatakse Vepuredi, peab sigade immuunsüsteem vaktsiinis sisalduvat toksiini võõraks ning tekitab selle vastu antikehi.
English: This summary was last updated in June 2017.
Estonian: Kokkuvõtte viimane uuendus: 06-2017.
English: Vepured contains adjuvants (aluminium hydroxide and DEAE-dextran) to enhance the immune response.
Estonian: Vepured sisaldab immuunvastuse tugevdamiseks adjuvante (alumiiniumhüdroksiidi ja dietüülaminoetüül(DEAE)-dekstraani).
English: How is Vepured used?
Estonian: Kuidas Vepuredi kasutatakse?
English: What benefits of Vepured have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Vepuredi kasulikkus?
English: Oedema disease is caused by a bacterial toxin (poison) known as verotoxin 2e that is produced by certain strains of Escherichia coli.
Estonian: Tursetõbe tekitab Escherichia coli teatud tüvede toodetav bakteriaalne toksiin (mürk), mida nimetatakse verotoksiin 2e-ks.
English: Vepured is given to piglets from 2 days of age as a single injection into the muscle in the neck.
Estonian: Vepuredi manustatakse sigadele alates 2. elupäevast ühe süstina kaelalihasesse.
English: How does Vepured work?
Estonian: Kuidas Vepured toimib?
English: In the future, if the animals are exposed to the bacteria producing the unmodified toxin, their immune system will be able to make antibodies against the toxin more quickly.
Estonian: Kui loomad modifitseerimata toksiini tootvate bakteritega hiljem uuesti
English: Vepured is available as a suspension for injection and can only be obtained with a prescription.
Estonian: Vepuredi turustatakse süstesuspensioonina ja see on retseptivaktsiin.
English: Hence, this has not been changed.
Estonian: Seega ei tehtud sinna muudatusi.
English: Drug Reactions and Interactions 2006.
Estonian: Adverse Drug Reactions and Interactions 2006.
English: • contraindications were sometimes relative rather than absolute.
Estonian: • vastunäidustused on mõnikord pigem suhtelised, aga mitte absoluutsed.
English: In several countries there was no information in section 4.2 on this group of patients.
Estonian: Mitmes riigis puudus lõigus 4.2 teave selle patsiendirühma kohta.
English: Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse
Estonian: Meyler's Side Effects of Drugs: The International Encyclopedia of
English: It presented in a succinct manner some important facts on these two molecules.
Estonian: Selles esitati lühidalt mõni tähtis fakt nende kahe osa kohta.
English: A total of 214 patients (age range 64 - 81 years) were included in this trial.
Estonian: Selle uuringus osales kokku 214 patsienti (vanuses 64-81 aastat).
English: • Aronson JK (editor).
Estonian: • Aronson, J. K. (koostaja).
English: Press <http://www.medicinescomplete.com/> (Accessed Sep-Nov 2009)
Estonian: Pharmaceutical Press <http://www.medicinescomplete.com/> (Vaadatud september-november
English: • Sweetman SC (editor), Martindale: The Complete Drug Reference 36.
Estonian: • Sweetman, S. C. (koostaja), Martindale: The Complete Drug Reference 36. London:
English: Specific treatment advice was not included as treatment protocols may vary between countries.
Estonian: Kindlaid nõuandeid raviks ei antud, sest raviprotokollid võivad eri riikides olla erinevad.
English: Combination therapy with antihypertensive agents is rarely necessary.
Estonian: Kombineeritud ravi hüpertensioonivastaste ravimitega on harva vajalik.
English: However, hydrochlorothiazide is currently listed as `safe' or `probably safe' by several authorities (e.g. European Porphyria Initiative http://www.porphyria-europe.com/03-drugs/drugs-and-porphyrias.asp; The Drug Data-base for Acute Porphyria http://www.drugs-porphyria.com.
Estonian: Praegu nimetavad mitmed ametiasutused hüdroklorotiasiidi siiski „ohutuks” või „tõenäoliselt ohutuks” (nt Euroopa porfüüriaalgatus, http://www.porphyria-europe.com/03drugs/drugs-and-porphyrias.asp; ägeda porfüüria ravimite andmebaas, http://www.drugsporphyria.com).
English: The paragraph ‘Clinical/Efficacy Studies' has been slightly rewording for more clarity.
Estonian: Lõigu „Kliinilise efektiivsuse uuringud” sõnastust on suurema selguse huvides pisut muudetud.
English: The CHMP agreed with such approach.
Estonian: Inimravimite komitee nõustus sellise lähenemisega.
English: Therefore, Vascace Plus is not recommended for patients with severe renal impairment (see section 4.3)”.
Estonian: Seetõttu ei soovitata Vascace Plusi kasutada raske neerupuudulikkusega patsientidel (vt lõik 4.3)”.
English: Overall summary of the scientific evaluation of Vascace Plus and associated names (see Annex I)
Estonian: Vascace Plusi ja sarnaste nimetuste (vt I lisa) teadusliku hindamise üldkokkuvõte
English: Furthermore, the addition of an ACE inhibitor may further attenuate this effect.
Estonian: Veelgi enam, ACE-inhibiitori lisamine võib seda toimet veelgi nõrgendada.
English: Also the MAH presented the studies published which evaluated the combination of cilazapril and hydrochlorothiazide: Pordy et al (1995; 1994), Martina et al (1994), Yodfat et al. (1994), and Sanchez
Estonian: Samuti esitles müügiloa hoidja avaldatud uuringuid, milles oli hinnatud tsilasapriili ja hüdroklorotiasiidi kombineeritud kasutamist: Pordy et al (1995; 1994), Martina et al (1994), Yodfat et al (1994) ning Sanchez (1989).
English: Section 4.5 Interaction with Other Medicinal Products and Other Forms of Interaction
Estonian: Lõik 4.5 - Koostoimed teiste ravimitega ja muud koostoimed
English: Over 600 of these patients received the cilazapril/hydrochlorothiazide combination for 6 months and more, and approximately 200 of these patients were treated with the combination for one year or longer.
Estonian: Rohkem kui 600 patsienti raviti tsilasapriili/hüdroklorotiasiidi kombinatsiooniga 6 kuud või kauem ja ligikaudu 200 patsienti raviti selle kombinatsiooniga ühe aasta jooksul või kauem.
English: The proposed summary of the safety profile has been updated by the MAH taking into account the most recent guidelines and the definition of “frequency” used in the studies as supporting evidence.
Estonian: Müügiloa hoidja on välja pakutud ohutusprofiili kokkuvõtet ajakohastanud, võttes arvesse kõige uuemaid juhiseid ja sageduse määratlust, mida on kasutatud toetavate tõenditena esitatud uuringutes.
English: Section 4.6 Pregnancy and Lactation
Estonian: Lõik 4.6 - Rasedus ja imetamine
English: The CHMP agreed to change the text “Pregnancy and lactation (see section 4.6)” under this section to “Second and third trimesters of pregnancy (see sections 4.4 and 4.6)”.
Estonian: Inimravimite komitee nõustus vastavas lõigus muutma teksti „Rasedus ja imetamine (vt lõiku 4.6)” kujule „Raseduse teine ja kolmas trimester (vt lõigud 4.4 ja 4.6)”.
English: Lipid profile
Estonian: Lipiidiprofiil
English: Information on pharmacokinetics of hydrochlorothiazide in special populations has been added to section 5.2.
Estonian: Eripopulatsioonides hüdroklorotiasiidi farmakokineetika teave on lisatud lõiku 5.2.
English: It is widely known that thiazides as a class can increase uric acid levels (Meyler; Martindale).
Estonian: Laialdaselt on teada, et tiasiidide ravimirühm võib suurendada kusihappe sisaldust (Meyler; Martindale).
English: Additional information was included in some Member States in warnings in respect of risk of hypotension, renovascular hypertension/renal artery stenosis, kidney transplantation, use in concomitant heart failure, anaemia, cough, ethnic groups, primary aldosteronism, and doping.
Estonian: Mõnes liikmesriigis lisati hoiatustele täiendavat teavet hüpotensiooni riski, renovaskulaarse hüpotensiooni / neeruarteri stenoosi, neerusiirdamise, kaasneva südamehaiguse korral kasutamise, aneemia, köha, etniliste rühmade, primaarse aldosteronismi ja dopingu kohta.
English: Treatment is difficult and rather infrequent, since patients with cirrhosis have a tendency towards low blood pressure.
Estonian: Ravi on keeruline ja üsna katkendlik, sest tsirroosiga patsientidel on kalduvus vererõhu languseks.
English: Differences in level of detail existed between Member States for special warnings and precautions for use.
Estonian: Hoiatuste ja ettevaatusabinõude kasutamisel võetavate meetmete üksikasjalikkuse osas oli liikmesriikide vahel erinevusi.
English: This was based on results of an epidemiological study which found that exposure to ACE inhibitors restricted to the first trimester of pregnancy was associated with increased risk of major congenital malformations including central nervous system and kidney malformations.
Estonian: Selle aluseks olnud tulemused olid saadud epidemioloogilises uuringus, milles leiti, et raseduse esimese trimestriga piirduv kokkupuude ACE-inhibiitoritega on seotud suurenenud riskiga raskete kaasasündinud väärarendite tekkimiseks, sealhulgas närvisüsteemi ja neeru väärarendite tekkeks.
English: In some SPCs, relative contraindications were discussed in section 4.4 (Special Warnings and Precautions), rather than in section 4.3;
Estonian: Mõnes ravimi omaduste kokkuvõttes käsitleti suhtelisi vastunäidustusi lõigus 4.4 (Hoiatused ja ettevaatusabinõud kasutamisel), aga mitte lõigus 4.3;
English: In one trial (protocol no. N2960C) it was shown that patients had an overall decrease in SDBP of 4.3 mm Hg before the addition of hydrochlorothiazide and 11.1 mm Hg after the addition of hydrochlorothiazide.
Estonian: Ühes uuringus (protokoll nr N2960C) näidati, et kokkuvõttes langes patsientide vererõhk enne hüdroklorotiasiidi lisamist 4,3 mmHg ja pärast hüdroklorotiasiidi lisamist 11,1 mmHg.
English: Moreover, according to the PhVWP recommendation, angiotensin converting enzyme inhibitors are contraindicated in second and third trimesters of pregnancy but not during the first trimester of pregnancy or lactation.
Estonian: Ravimiohutuse töörühma soovituste kohaselt on angiotensiini muundava ensüümi inhibiitorid vastunäidustatud raseduse teisel ja kolmandal trimestril, kuid mitte raseduse esimesel trimestril ning imetamise ajal.
English: In the SPC of several countries the same or slightly modified wording was used.
Estonian: Mitmetes riikides kasutati ravimi omaduste kokkuvõttes samasugust või pisut muudetud sõnatust.
English: • lack of data concerning safety in specific patients groups was the only justification for listing certain contraindications;
Estonian: • teatud vastunäidused olid loetletud üksnes põhjusel, et puudusid teatud patsiendirühmade ohutusandmed;
English: Children The CHMP agreed that the use of Vascace Plus is not recommended in children.
Estonian: Lapsed Inimravimite komitee nõustus, et Vascace Plusi kasutamine lastel ei ole soovitatav.
English: Some SPCs recommend that fluid and electrolyte disturbances should be corrected before starting treatment.
Estonian: Mõnes ravimi omaduste kokkuvõttes soovitatakse korrigeerida vedeliku- ja elektrolüüditasakaalu häired enne ravi alustamist.
English: The proposed text included a general statement concerning emergency treatment of angioedema.
Estonian: Väljapakutud tekst sisaldas üldist teavet esmaabi andmise kohta angioödeemi korral.
English: Electrolyte disturbances including hypokalaemia, hyponatraemia and dehydration are mainly associated with thiazides, whilst ACE inhibitors can cause hyperkalaemia.
Estonian: Elektrolüütide tasakaalu häired, nagu hüpokaleemia, hüponatreemia ja dehüdratsioon, on peamiselt seotud tiasiididega, samal ajal kui ACE-inhibiitorid võivad põhjustada hüperkaleemiat.
English: A very cautious treatment is required due to the therapeutic properties of cilazapril and a cross reference to section 4.4 has been added.
Estonian: Tsilasapriili raviomaduste tõttu tuleb ravimisel olla väga ettevaatlik ja lõiku 4.4. lisati vastav ristviide.
English: Doubling the initial dose (5.0 mg cilazapril 12.5 mg hydroclorthiazide) resulted in a further increase in efficacy.
Estonian: Esialgse annuse kahekordistamine (5,0 mg tsilasapriili ja 12,5 mg hüdroklorotiasiidi) tõi kaasa efektiivsuse edasise kasvu.
English: The CHMP endorsed most of the MAH's proposal except for pregnancy.
Estonian: Inimravimite komitee kinnitas enamiku müügiloa hoidja ettepanekutest, välja arvatud rasedust käsitleva osa.
English: The warning may be based on concerns about crossreactivity with sulfonamide antibiotics, which are know to aggravate porphyria.
Estonian: Hoiatuse aluseks võib olla võimalus risttoimete tekkeks sulfoonamiidantibiootikumitega, mis teadaolevalt raskendavat porfüüriat.
English: The CHMP agreed with the MAH proposal to include this adverse effect of thiazides in section 4.8 but not under 4.4.
Estonian: Inimravimite komitee nõustus müügiloa hoidja ettepanekuga tuua see tiasiidide kõrvalmõju ära lõigus 4.8, aga mitte lõigus 4.4.
English: Section 4.4 Special Warnings and Precautions for Use
Estonian: Lõik 4.4 - Hoiatused ja ettevaatusabinõud kasutamisel
English: Section 5.2 Pharmacokinetic properties
Estonian: Lõik 5.2 Farmakokineetilised omadused
English: A diuretic such as hydrochlorothiazide enhances efficacy of the ACE inhibitor by stimulating the renin-angiotensin system and shifting the hypertensive state to a more renin-dependent condition.
Estonian: Diureetikumid, nagu hüdroklorotiasiid, suurendavad ACE-inhibiitorite efektiivsust, stimuleerides reniin-angiotensiini süsteemi ja muutes vererõhku reniinist rohkem sõltuvaks.
English: Vascace Plus is a combination of cilazapril (an angiotensin-converting enzyme inhibitor) and hydrochlorothiazide (a thiazide-diuretic agent).
Estonian: Vascace Plus on kombinatsioon tsilasapriilist (angiotensiini konverteeriva ensüümi inhibiitor) ja hüdroklorotiasiidist (tiasiiddiureetikum).